Conclusions
The authors propose that nephrocalcinosis under these circumstances should be called "acute phosphate nephropathy" because it appears to be caused by phosphate ingestion, not hypercalcemia. They conclude that acute phosphate nephropathy may be underrecognized in patients undergoing colon preparation with sodium phosphate laxatives. Women, older patients, and those taking ACE-I or ARB antihypertensive agents may be at special risk.
This is a preview of subscription content, log in via an institution to check access.
References
Markowitz GS, Nasr SH, Klein P, et al.: Renal failure and acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004, 35:675–684.
Desmeules S, Bergeron MJ, Isenring P: Acute phosphate nephropathy and renal failure. N Engl J Med 2003, 349:1006–1007.
Rex DK, Balaban DH, Bond JH, et al.: Oral sodium phosphate solution for bowel preparation: Literature review and recommendations of an industry-sponsored advisory panel regarding safe and effective use. Available at http://www. phosphosoda.com/professionals/pdf/OSPS_document.pdf (Accessed 6/11/06).
FDA Information for Healthcare Professionals. Oral sodium phosphate products for bowel cleansing. Available at http:// www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP. pdf (Accessed 6/11/06)
Food and Drug Administration Science Background Paper: Acute phosphate nephropathy and renal failure associated with the use of oral sodium phosphate bowel cleansing products. Available at: http://www.fda.gov/cder/drug/Infopage/OSP_ solution/science_background.pdf (Accessed 6/11/06)
FDA Patient Information Sheet. Oral sodium phosphate products for bowel cleansing. Available at http://www. fda.gov/cder/drug/InfoSheets/patient/OSP_solutionPIS.pdf (Accessed 6/11/06)
Rights and permissions
About this article
Cite this article
Schiller, L.R. Clinical Trials Report. Curr Gastroenterol Rep 8, 399–400 (2006). https://doi.org/10.1007/s11894-006-0025-5
Issue Date:
DOI: https://doi.org/10.1007/s11894-006-0025-5